GlassScriptPhysician profile
Debora S Bruno
NPI 1437100302
$57,320.36
in general payments reported to CMS, 2019-2025
22 companies · $7,396 in 2025
The $7,396 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.42 · 2021: $11K · 2022: $8,772 · 2023: $16K · 2024: $15K · 2025: $7,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Travel and Lodging: $6,007 · Honoraria: $4,900 · Food and Beverage: $1,537 · Education: $45.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,249.50 |
| Travel and Lodging | $6,007.22 |
| Honoraria | $4,900.00 |
| Food and Beverage | $1,537.04 |
| Education | $45.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,647.49 | 2019-2025 | Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $14,178.73 | 2021-2023 | Opdivo |
| Novocure INC. | $6,375.60 | 2023-2024 | Optune Lua (Novottf-200t) |
| Daiichi Sankyo INC. | $5,619.65 | 2021-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $4,063.40 | 2021-2023 | |
| Regeneron Pharmaceuticals, INC. | $3,434.17 | 2023-2024 | Libtayo |
| Amgen INC. | $3,245.00 | 2022 | |
| Merck Sharp & Dohme LLC | $2,465.70 | 2023-2025 | Keytruda |
| Ethicon US, LLC | $124.50 | 2022 | |
| Astrazeneca Uk Limited | $49.99 | 2023 | |
| Lilly USA, LLC | $47.70 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.21 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.01 | 2023 | |
| Eisai INC. | $14.22 | 2019 | |
| Mirati Therapeutics, INC. | $13.99 | 2024 | Krazati |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.